171 related articles for article (PubMed ID: 7967683)
1. Recombinant platelet factor 4 reversal of heparin in human cardiopulmonary bypass blood.
Williams RD; D'Ambra MN; Maione TE; Lynch KE; Keene DF
J Thorac Cardiovasc Surg; 1994 Nov; 108(5):975-83. PubMed ID: 7967683
[TBL] [Abstract][Full Text] [Related]
2. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass.
Bernabei A; Gikakis N; Maione TE; Kowalska MA; Yan Z; Niewiarowski S; Edmunds LH
J Thorac Cardiovasc Surg; 1995 Apr; 109(4):765-71. PubMed ID: 7715225
[TBL] [Abstract][Full Text] [Related]
3. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
[TBL] [Abstract][Full Text] [Related]
4. Heparin neutralization by recombinant platelet factor 4 and protamine.
Levy JH; Cormack JG; Morales A
Anesth Analg; 1995 Jul; 81(1):35-7. PubMed ID: 7598278
[TBL] [Abstract][Full Text] [Related]
5. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass.
Demma L; Levy JH
Anesth Analg; 2012 Dec; 115(6):1273-8. PubMed ID: 22859690
[TBL] [Abstract][Full Text] [Related]
6. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
7. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans.
Dehmer GJ; Lange RA; Tate DA; Pirwitz M; Daniel W; Fisher M; Bonnem EM
Circulation; 1996 Nov; 94(9 Suppl):II347-52. PubMed ID: 8901773
[TBL] [Abstract][Full Text] [Related]
9. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes.
Cook JJ; Niewiarowski S; Yan Z; Schaffer L; Lu W; Stewart GJ; Mosser DM; Myers JA; Maione TE
Circulation; 1992 Mar; 85(3):1102-9. PubMed ID: 1537108
[TBL] [Abstract][Full Text] [Related]
10. The effects of heparinase 1 and protamine on platelet reactivity.
Ammar T; Fisher CF
Anesthesiology; 1997 Jun; 86(6):1382-6. PubMed ID: 9197309
[TBL] [Abstract][Full Text] [Related]
11. Impact of protamine dose on activated clotting time and thromboelastography in infants and small children undergoing cardiopulmonary bypass.
Gautam NK; Schmitz ML; Harrison D; Zabala LM; Killebrew P; Belcher RH; Prodhan P; McKamie W; Norvell DC
Paediatr Anaesth; 2013 Mar; 23(3):233-41. PubMed ID: 23279140
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of recombinant platelet factor 4 and protamine sulfate for heparin neutralization: clotting and clearance studies in rat.
Korutla LN; Stewart GJ; Lasz EC; Maione TE; Niewiarowski S
Thromb Haemost; 1994 May; 71(5):609-14. PubMed ID: 8091389
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
[TBL] [Abstract][Full Text] [Related]
14. Platelet-activating protamine-heparin-antibodies lead to higher protamine demand in patients undergoing cardiac surgery.
Grieshaber P; Bakchoul T; Wilhelm J; Wagner A; Wollbrück M; Böning A; Sachs U
J Thorac Cardiovasc Surg; 2015 Oct; 150(4):967-73.e1. PubMed ID: 26298870
[TBL] [Abstract][Full Text] [Related]
15. Inactivated antithombin as anticoagulant reversal in a rat model of cardiopulmonary bypass: a potent and potentially safer alternative to protamine.
Bianchini EP; Sebestyen A; Abache T; Bourti Y; Fontayne A; Richard V; Tamion F; Plantier JL; Doguet F; Borgel D
Br J Haematol; 2018 Mar; 180(5):715-720. PubMed ID: 29363751
[TBL] [Abstract][Full Text] [Related]
16. The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT).
Bode AP; Castellani WJ; Hodges ED; Yelverton S
Thromb Haemost; 1991 Aug; 66(2):213-7. PubMed ID: 1771614
[TBL] [Abstract][Full Text] [Related]
17. Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine?
Gertler R; Wiesner G; Tassani-Prell P; Braun SL; Martin K
J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):981-6. PubMed ID: 21315618
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
[TBL] [Abstract][Full Text] [Related]
19. Effect of heparin reversal and fresh platelet transfusion on platelet emboli post-cardiopulmonary bypass in a pig model.
Dewanjee MK; Wu SM; Hsu LC
ASAIO J; 2000; 46(3):313-8. PubMed ID: 10826743
[TBL] [Abstract][Full Text] [Related]
20. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin.
Shanberge JN; Quattrociocchi-Longe TM; Martens MH
Thromb Res; 1987 Apr; 46(1):89-100. PubMed ID: 3590116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
